RxDoctor Payments Data

Kanu Patel, MD

Internal Medicine · Greenville, ALNPI 1487630505

Payments from drug & device makers

$883in general payments, 2019–2025

Across 56 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$304
  • Lilly USA, LLC$143
  • AstraZeneca$121
  • Boehringer Ingelheim$102
  • Merck$73
  • Johnson & Johnson$68
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$883 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$91,732
Medicare patients
139
Services billed
5,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide118$147,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$65,037
RybelsusSemaglutide43$64,642
JanuviaSitagliptin Phosphate47$55,984
EliquisApixaban61$52,909
TrulicityDulaglutide36$42,854
XareltoRivaroxaban37$42,054
OzempicSemaglutide20$35,329
JardianceEmpagliflozin19$33,625
FarxigaDapagliflozin Propanediol49$29,260
Janumet XrSitagliptin Phos/Metformin Hcl22$22,565
JanumetSitagliptin Phos/Metformin Hcl30$19,913
Breo ElliptaFluticasone/Vilanterol31$19,895
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro36$11,415
VascepaIcosapent Ethyl15$6,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$143$190,345154 claims
Novo NordiskRybelsus, Ozempic$304$99,97163 claims
MerckJanuvia, Janumet Xr, Janumet$73$98,46299 claims
Johnson & JohnsonXarelto$68$42,05437 claims
Boehringer IngelheimJardiance$102$33,62519 claims
AstraZenecaFarxiga$121$29,26049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Greenville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →